

The new claims are provided below in clean form. Per 37 C.F.R. §1.121, new claims are also shown in Appendix A with notations to indicate changes made (for convenience, all pending claims, including those added hereby, are provided in Appendix A).

21. (New) An isolated polypeptide comprising an amino acid sequence that is at least 95% identical with SEQ ID NO:2, wherein the polypeptide initiates or sustains inflammation.

22. (New) The polypeptide of claim 21 wherein the polypeptide is SEQ ID NO:2.

23. (New) An isolated polypeptide comprising amino acid residues 21 to 452 of SEQ ID NO:2.

24. (New) The polypeptide of claim 23 comprising amino acid residues 21 to 677 of SEQ ID NO:2.

25. (New) The polypeptide of claim 23 wherein the polypeptide is SEQ ID NO:2.

26. (New) The polypeptide of claim 23 further comprising a signal secretory sequence.

27. (New) The polypeptide of claim 26 wherein the signal secretory sequence comprises amino acid residues 1 to 20 of SEQ ID NO:2.

28. (New) The polypeptide of claim 23 further comprising an antibody fragment.

29. (New) The polypeptide of claim 23 further comprising a detectable label.

30. (New) The polypeptide of claim 23 further comprising an affinity tag.

31. (New) An isolated polypeptide comprising an amino acid sequence that is at least 95% identical with SEQ ID NO:10, wherein the polypeptide initiates or sustains inflammation.

32. (New) The polypeptide of claim 31 wherein the polypeptide is SEQ ID NO:10.

33. (New) An isolated polypeptide comprising amino acid residues 21 to 435 of SEQ ID NO:10.

34. (New) The polypeptide of claim 33 comprising amino acid residues 21 to 673 of SEQ ID NO:10.

35. (New) The polypeptide of claim 33 wherein the polypeptide is SEQ ID NO:10.

36. (New) The polypeptide of claim of claim 33 further comprising a signal secretory sequence.

37. (New) The polypeptide of claim of claim 36 wherein the signal secretory sequence comprises amino acid residues 1 to 20 of SEQ ID NO:10.

38. (New) The polypeptide of claim of claim 33 further comprising an antibody fragment.

39. (New) The polypeptide of claim of claim 33 further comprising a detectable label.

40. (New) The polypeptide of claim of claim 33 further comprising an affinity tag.

41. (New) An isolated polypeptide comprising a soluble amino acid sequence that is at least 95% identical to amino acid residues 21 to 452 of SEQ ID NO:2, wherein the polypeptide inhibits inflammation.

Applicants: Presnell et al.

Serial No.: 09/608,918

Filed: June 30, 2000

For: INTERLEUKIN-17 RECEPTOR HOMOLOGUE (As Amended)

---

42. (New) The isolated polypeptide of claim 41 wherein the polypeptide is amino acid residues 21 to 452 of SEQ ID NO:2.

43. (New) An isolated polypeptide comprising a soluble amino acid sequence that is at least 95% identical to amino acid residues 21 to 435 of SEQ ID NO:10, wherein the polypeptide inhibits inflammation.

44. (New) The isolated polypeptide of claim 43 wherein the polypeptide is amino acid residues 21 to 435 of SEQ ID NO:10.

---